Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P150004/S100

Proclaim DRG IPG

ABBOTT MEDICAL · Decision date Sep 23, 2026

MEDTECHLEDGER EXPLANATIONP150004/S100

What did the FDA approve?

FDA approved supplement S100 to PMA P150004 on September 23, 2026. The supplement covers a material change to the encapsulant used in the printed circuit board assembly during manufacture of the Proclaim Spinal Cord Stimulator, Proclaim Dorsal Root Ganglion stimulator, and Infinity Deep Brain Stimulator Implantable Pulse Generator devices. The applicant is Abbott Medical, and the product code is PMP.

The supplement type is Real-Time Process, and the stated reason is Change Design/Components/Specifications/Material. The decision field is APPR. The source statement does not describe the encapsulant chemistry, the manufacturing step affected, or any testing performed. No safety or effectiveness conclusion is present in the supplied fields.

FDA approval order statement

approval for a material change to the encapsulant used in the printed circuit board assembly (PCBA) during the manufacture of the Proclaim Spinal Cord Stimulator (SCS), Proclaim Dorsal Root Ganglion (DRG) stimulator and Infinity Deep Brain Stimulator (DBS) Implantable Pulse Generator (IPG) devices.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Neurology
Decision date
Sep 23, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P150004/S100
Regulatory pathway
PMA supplement
Product code
PMP
Decision code
APPR
Decision date
Sep 23, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Dorsal root ganglion stimulator for pain relief.

Product code
PMP
FDA device class
3

For the original device and its historical approval scope, see PMA P150004. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P150004 · Original PMA

    Axium Neurostimulator System

  2. P150004/S100 received

    Application receipt date recorded by FDA.

  3. P150004/S100 · FDA decision

    Real-Time Process

  4. P150004/S101 · Related supplement

    Dorsal Root Ganglion Stimulation (DRG) EPG

Timeline entries are records held by MedtechLedger for P150004. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P150004

Product / regulatory recordCompanyPathwayDecision dateSource
ABBOTT MEDICALPMA approvalFeb 11, 2016FDA
ABBOTT MEDICALPMA supplementOct 28, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Medical

Headquarters
Not reported
Brand website
abbott.com
FDA applicant address
6901 Preston Rd., Plano, TX, 75024

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records